Liposomal daunorubicin as treatment for Kaposi's sarcoma
about
The Smart Drug Delivery System and Its Clinical PotentialNanoinformatics knowledge infrastructures: bringing efficient information management to nanomedical researchLiposomal Formulations in Clinical Use: An Updated Review.PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway.Daunorubicin-TiO2 nanocomposites as a "smart" pH-responsive drug delivery systemMultifunctional, stimuli-sensitive nanoparticulate systems for drug deliveryUse of short interfering RNA delivered by cationic liposomes to enable efficient down-regulation of PTPN22 gene in human T lymphocytesChallenges and opportunities in the advancement of nanomedicines.Nanotechnology and Pediatric Cancer: Prevention, Diagnosis and TreatmentBilateral Chest X-Ray Shadowing and Bilateral leg lesions - A case of Pulmonary Kaposi Sarcoma.Current trends in the use of liposomes for tumor targetingFluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity.Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.The influence of surface charge on serum protein interaction and cellular uptake: studies with dendritic polyglycerols and dendritic polyglycerol-coated gold nanoparticles.Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution.Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.Topoisomerases as anticancer targets.Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies.
P2860
Q26744837-46C5EDCB-85D2-4138-9ED1-99BEB7A42636Q28658443-D6AA2C7A-CEC7-422B-A3A3-E13EFF4254EDQ33850427-74DEC682-E540-4619-9D49-6E128FDE03F4Q34982384-90149934-FB37-4D41-95A6-014965800C59Q35686927-72D25AE8-7694-4B94-9C11-64B62D02BBC0Q35809872-FD3A7CB9-DA01-4698-BAFE-EA283E19B31FQ36355094-5CBD1128-00D5-4799-AD93-3FEDB608B1F0Q36417295-993E4D25-C971-4CCC-BD99-B02DE401B30DQ36654099-82EDEF23-BE76-40CB-B48B-9DD0448AC8EAQ36935830-4340E306-61E5-4F37-B3C9-9DA73E47F419Q38126543-A21F8CD2-CE08-4C11-9FDA-BB566031EF1EQ38274182-E0694C56-7E8A-489F-A04E-8E109260F398Q39794624-6FD76A0F-2E3F-49A5-8BD0-56C39938CB87Q41881248-ED81A9C1-DDFB-41BD-A74A-C716C2CEA9C4Q41905223-748AB660-7737-474C-B149-A63A64249ACFQ47707153-A14D2089-8F9E-4CBE-8D1C-A04E4D81343AQ49832269-A851AAFC-4E7C-4A44-8739-60443FDE4136Q50060960-489E690A-D0F4-40E5-B716-97D8864BDDB7Q55652135-DEC291A9-D914-4B9C-82F5-9C68F9771893
P2860
Liposomal daunorubicin as treatment for Kaposi's sarcoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Liposomal daunorubicin as treatment for Kaposi's sarcoma
@en
Liposomal daunorubicin as treatment for Kaposi's sarcoma.
@nl
type
label
Liposomal daunorubicin as treatment for Kaposi's sarcoma
@en
Liposomal daunorubicin as treatment for Kaposi's sarcoma.
@nl
prefLabel
Liposomal daunorubicin as treatment for Kaposi's sarcoma
@en
Liposomal daunorubicin as treatment for Kaposi's sarcoma.
@nl
P2860
P921
P1476
Liposomal daunorubicin as treatment for Kaposi's sarcoma
@en
P2093
Christin E Petre
P2860
P304
P407
P50
P577
2007-01-01T00:00:00Z